Our History
More than 100 combined years of research produced a series of patents that LifePulse™ Corporation acquired in 2020, as Pulsed Electrical Fields became one of the most important technologies in biotech. LifePulse™ was founded by Gary Strange in 2018.
Our Mission
To make this technology available in the United States first, then worldwide — beginning with pancreatic tumor trials in human medicine.
Our Patents
$37M of non-dilutive research grants from the NIH, NCI and others have produced our growing list of patents that are the foundation of the IntelliPulse™ platform.
Our four divisions
LifePulse™ Corporation
Since March 2022, hundreds of dogs, cats, and horses have been treated for dozens of indications, with devices in clinical use across the United States.
IntelliPulse™ Platform
A platform for cellular delivery of therapeutics — the first major advancement in Pulsed Electrical Fields in a generation.
Drug Development
Pharmaceuticals developed specifically for use in combination with the IntelliPulse™ system.
Research Division
We will soon begin a translational clinical trial in canine melanoma with the primary site at the Purdue University Veterinary College.
Ethics & Sustainability
LifePulse™ Corporation is committed to responsible research conduct, humane treatment standards in veterinary practice, and transparent reporting of clinical outcomes.